ArticleMethodsX2022
Modularisation of published and novel models toward a complex KIR2DL4 pathway in pbNK cell.
Article in MethodsX, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KIR2DL4 is an interesting receptor expressed on the peripheral blood natural killer (pbNK) cell as it can be either activating or inhibitory depending on the amino acid residues in the domain. This model uses mathematical modelling to investigate the downstream effects of natural killer cells' activation (KIR2DL4) receptor after stimulation by key ligand (HLA-G) on pbNK cells. Development of this large pathway is based on a comprehensive qualitative description of pbNKs' intracellular signalling pathways leading to chemokine and cytotoxin secretion, obtained from the KEGG database (https://www.genome.jp/pathway/hsa04650). From this qualitative description we built a quantitative model for the pathway, reusing existing curated models where possible and implementing new models as needed. This model employs a composite approach for generating modular models. The approach allows for the construction of large-scale complex model by combining component of sub-models that can be modified individually. This large pathway consists of two published sub-models; the Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.